Vascular Outcomes studY of ASA alonG with rivaroxaban in Endovascular or surgical limb Revascularization for peripheral artery disease (PAD).

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 6564

Inclusion Criteria

Age =50, Documented moderate to severe symptomatic lower extremity peripheral artery occlusive disease, Technically successful peripheral infra-inguinal revascularization within the last 7 days prior to randomization
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 2210
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 4290

Exclusion Criteria

Patients undergoing revascularization for asymptomatic peripherial
artery disease, mild
claudication without functional limitation or major tissue loss (including
severe ischemic ulcers or gangrene) of the index leg
- Patients undergoing revascularization of the index leg to treat an
asymptomatic or minimally symptomatic restenosis of a bypass graft or
target lesion restenosis
- Prior revascularization on the index leg within 8 weeks of the
qualifying revascularization
- Planned dual antiplatelet therapy use for the qualifying
revascularization procedure of clopidogrel in addition to Aspirin for >30
days after the qualifying revascularization procedure
- Planned dual antiplatelet therapy use for any other indication(s) with
any P2Y12 antagonists in addition to Aspirin after the qualifying
revascularization procedure

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Phase 1

Bayer AG

Updated 8/18/2020

An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis - CASSIOPEA

Not Applicable

sanofi-aventis Recherche & Development,

Updated 9/4/2023

An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis - CASSIOPEA

sanofi-aventis recherche & développement

Updated 3/19/2012

An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis - CASSIOPEA

sanofi-synthelabo recherche

Updated 3/19/2012

An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis - CASSIOPEA

sanofi-aventis recherche et développement

Updated 3/19/2012

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Phase 1

Bayer AG

Updated 3/22/2021

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Phase 1

Bayer AG

Updated 9/9/2024

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Phase 1

Bayer AG

Updated 9/9/2024

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Phase 1

Bayer AG

Updated 11/9/2020

An international, multicenter, randomized, double-blind, placebocontrolled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures

CompletedPhase 3

Bayer Healthcare AG

Updated 4/23/2024

Vascular Outcomes studY of ASA alonG with rivaroxaban in Endovascular or surgical limb Revascularization for peripheral artery disease (PAD).

Recruitment & Eligibility

Study & Design

Related Trials

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities.

Clinical Trial Alerts

Clinical Trial Alerts